Giacobini E, Cuello AC, Fisher A (2022)
Reimagining cholinergic therapy for Alzheimer's disease
Brain 145: 2250

Fisher A, Carney G, Bassett K, Maclure KM, Dormuth CR (2019)
Policy-induced selection bias in pharmacoepidemiology: The example of coverage for Alzheimer's medications in British Columbia
Pharmacoepidemiol Drug Safety 28: 1067

Fisher A, Carney G, Bassett K, Dormuth CR (2017)
Tolerability of Cholinesterase Inhibitors: A Population-Based Study of Persistence, Adherence, and Switching
Drugs & Aging 34: 221

Fisher A, Carney G, Bassett K, Chappell NL (2016)
Cholinesterase Inhibitor Utilization: The Impact of Provincial Drug Policy on Discontinuation
Value Health 19: 688

Welt T, Kulic L, Hoey SE, McAfoose J, Spani C, Chadha AS, Fisher A, Nitsch RM (2015)
Acute Effects of Muscarinic M1 Receptor Modulation on AbetaPP Metabolism and Amyloid-beta Levels in vivo: A Microdialysis Study
J Alzheimers Dis 46: 971

Fisher A (2012)
Cholinergic modulation of amyloid precursor protein processing with emphasis on M1 muscarinic receptor: perspectives and challenges in treatment of Alzheimer's disease
Journal of Neurochemistry 120 Suppl 1: 22

Alfa Cisse M, Louis K, Braun U, Mari B, Leitges M, Slack BE, Fisher A, Auberger P, Checler F, Vincent B (2008)
Isoform-specific contribution of protein kinase C to prion processing
Molecular & Cellular Neurosciences 39: 400

Fisher A (2008)
Cholinergic treatments with emphasis on m1 muscarinic agonists as potential disease-modifying agents for Alzheimer's disease
Neurotherapeutics 5: 433

Alfa Cisse M, Sunyach C, Slack BE, Fisher A, Vincent B, Checler F (2007)
M1 and M3 muscarinic receptors control physiological processing of cellular prion by modulating ADAM17 phosphorylation and activity
Journal of Neuroscience 27: 4083

Madan A, Fisher A, Jin L, Chapman D, Bozigian HP (2007)
In vitro metabolism of indiplon and an assessment of its drug interaction potential
Xenobiotica 37: 736

Fisher A, Brandeis R, Pittel Z, Haring R, Sparks L, Beach TG, Bons N, Maestre-Frances N, Bar-Ner N, Kliger-Spatz M, Natan N, Marcovitch I, Hartmann T (2004)
Poster (46) Major hallmarks in alzheimer's disease (ad) can beneficially be modulated by M1 muscarinic agonists - an added value vs. cholinesterase inhibitors
In: Cholinesterases in the Second Millennium: Biomolecular and Pathological Aspects (Inestrosa NC, Campos EO) P. Universidad Catolica de Chile-FONDAP Biomedicina: 345

Fisher A, Pittel Z, Haring R, Bar-Ner N, Kliger-Spatz M, Natan N, Egozi I, Sonego H, Marcovitch I, Brandeis R (2003)
M1 muscarinic agonists can modulate some of the hallmarks in Alzheimer's disease: implications in future therapy
Journal of Molecular Neuroscience 20: 349

O'Neill J, Siembieda DW, Crawford KC, Halgren E, Fisher A, Fitten LJ (2003)
Reduction in distractibility with AF102B and THA in the macaque
Pharmacol Biochem Behav 76: 301

Fisher A (2000)
Therapeutic strategies in Alzheimer's disease: M1 muscarinic agonists
Japanese Journal of Pharmacology 84: 101

Fisher A, Michaelson DM, Brandeis R, Haring R, Chapman S, Pittel Z (2000)
M1 muscarinic agonists as potential disease-modifying agents in Alzheimer's disease. Rationale and perspectives
Annals of the New York Academy of Sciences 920: 315

Fitten LJ, Ortiz F, Siembieda DW, O'Neill J, Halgren E, Fisher A (1999)
Reduction of motoric agitation and restlessness by AF102B and tacrine in the macaque
J Neuropsychiatry Clin Neurosci 11: 79

Genis I, Fisher A, Michaelson DM (1999)
Site-specific dephosphorylation of tau of apolipoprotein E-deficient and control mice by M1 muscarinic agonist treatment
Journal of Neurochemistry 72: 206

O'Neill J, Fitten LJ, Siembieda DW, Crawford KC, Halgren E, Fisher A, Refai D (1999)
Divided attention-enhancing effects of AF102B and THA in aging monkeys
Psychopharmacology (Berl) 143: 123

Pittel Z, Fisher A, Eshhar N, Haring R, Heldman E (1999)
Poster: Effect of muscarinic stimulation on beta-amyloid precursor protein processing in rat brain and primary cultures
Life Sciences 64: 572

Chapman S, Fisher A, Weinstock M, Brandies R, Shohami E, Michaelson DM (1998)
The effects of the acetylcholinesterase inhibitor ENA713 and the M1 agonist AF150(S) on apolipoprotein E deficient mice
Journal de Physiologie Paris 92: 299

Fisher A, Brandeis R, Haring R, Eshhar N, Heldman E, Karton Y, Eisenberg O, Meshulam H, Marciano D, Bar-Ner N, Pittel Z (1998)
Novel m1 muscarinic agonists in treatment and delaying the progression of Alzheimer's disease: An unifying hypothesis
Journal de Physiologie (Paris) 92: 337

Fisher A, Brandeis R, Chapman S, Pittel Z, Michaelson DM (1998)
M1 muscarinic agonist treatment reverses cognitive and cholinergic impairments of apolipoprotein E-deficient mice
Journal of Neurochemistry 70: 1991

O'Neill J, Fitten LJ, Siembieda D, Halgren E, Kim E, Fisher A, Perryman K (1998)
Effects of AF102B and tacrine on delayed match-to-sample in monkeys
Prog Neuropsychopharmacol Biological Psychiatry 22: 665

Haring R, Eshhar N, Heldman E, Marciano D, Kloog Y, Fisher A (1997)
Poster: An M1 selective agonist AF102b, as a potential drug in treatment of Alzheimer's disease: Biochemical and pharmacological properties
Life Sciences 60: 1183

Danenberg HD, Haring R, Fisher A, Pittel Z, Gurwitz D, Heldman E (1996)
Dehydroepiandrosterone (DHEA) increases production and release of Alzheimer's amyloid precursor protein
Life Sciences 59: 1651

Fisher A, Heldman E, Gurwitz D, Haring R, Karton Y, Meshulam H, Pittel Z, Marciano D, Brandeis R, Sadot E, Barg Y, Pinkas-Kramarski R, Vogel Z, Ginzburg I, Treves TA, Verchovsky R, Klimowsky S, Korczyn AD (1996)
M1 agonists for the treatment of Alzheimer's disease. Novel properties and clinical update
Annals of the New York Academy of Sciences 777: 189

Pittel Z, Heldman E, Barg J, Haring R, Fisher A (1996)
Muscarinic control of amyloid precursor protein secretion in rat cerebral cortex and cerebellum
Brain Research 742: 299

Danenberg HD, Haring R, Heldman E, Gurwitz D, Ben-Nathan D, Pittel Z, Zuckerman A, Fisher A (1995)
Dehydroepiandrosterone augments M1-muscarinic receptor-stimulated amyloid precursor protein secretion in desensitized PC12M1 cells
Annals of the New York Academy of Sciences 774: 300

Gurwitz D, Haring R, Heldman E, Fraser CM, Manor D, Fisher A (1994)
Discrete activation of transduction pathways associated with acetylcholine m1 receptor by several muscarinic ligands
European Journal of Pharmacology 267: 21

Fisher A, Heldman E, Gurwitz D, Haring R, Barak D, Meshulam H, Marciano D, Brandeis R, Pittel Z, Segal M, et al. (1993)
Selective signaling via unique M1 muscarinic agonists
Annals of the New York Academy of Sciences 695: 300

Fisher A, Karton Y, Heldman E, Gurwitz D, Haring R, Meshulam H, Brandeis R, Pittel Z, Segall Y, Marciano D, et al. (1993)
Progress in medicinal chemistry of novel selective muscarinic agonists
Drug Des Discov 9: 221

Pittel Z, Fisher A, Vogel Z, Heldman E (1993)
Poster: Transmembrane signaling of M1 muscarinic receptors in the rat brain and cell cultures
Life Sciences 52(5-6): 565

Riekkinen P, Jr., Riekkinen M, Fisher A, Ekonsalo T, Sirvio J (1993)
Effects of muscarinic receptor agonists and anticholinesterase drugs on high voltage spindles and slow waves
European Journal of Pharmacology 240: 1

Pittel Z, Cohen S, Fisher A, Heldman E (1992)
Differential long-term effect of AF64A on [3H]ACh synthesis and release in rat hippocampal synaptosomes
Brain Research 586: 148

Segal M, Fisher A (1992)
AF102B, a muscarinic M1 receptor agonist, mimics some effects of acetylcholine on neurons of rat hippocampus slices
European Journal of Pharmacology 220: 103

Fisher A, Brandeis R, Karton I, Pittel Z, Gurwitz D, Haring R, Sapir M, Levy A, Heldman E (1991)
(+-)-cis-2-methyl-spiro(1,3-oxathiolane-5,3')quinuclidine, an M1 selective cholinergic agonist, attenuates cognitive dysfunctions in an animal model of Alzheimer's disease
Journal of Pharmacology & Experimental Therapeutics 257: 392

Potter LT, Ballesteros LA, Bichajian LH, Ferrendelli CA, Fisher A, Hanchett HE, Zhang R (1991)
Evidence of paired M2 muscarinic receptors
Molecular Pharmacology 39: 211

Mochida S, Mizobe F, Fisher A, Kawanishi G, Kobayashi H (1988)
Dual synaptic effects of activating M1-muscarinic receptors, in superior cervical ganglia of rabbits
Brain Research 455: 9

Sandberg K, Schnaar RL, McKinney M, Hanin I, Fisher A, Coyle JT (1985)
AF64A: an active site directed irreversible inhibitor of choline acetyltransferase
Journal of Neurochemistry 44: 439

Mantione CR, Fisher A, Hanin I (1984)
Possible mechanisms involved in the presynaptic cholinotoxicity due to ethylcholine aziridinium (AF64A) in vivo
Life Sciences 35: 33

Sandberg K, Hanin I, Fisher A, Coyle JT (1984)
Selective cholinergic neurotoxin: AF64A's effects in rat striatum
Brain Research 293: 49

Szerdahelyi P, Kasa P, Fisher A, Hanin I (1984)
Effects of the cholinotoxin, AF64A, on neuronal trace-metal distribution in the rat hippocampus and neocortex
Histochemistry 81: 497

Walsh TJ, Tilson HA, DeHaven DL, Mailman RB, Fisher A, Hanin I (1984)
AF64A, a cholinergic neurotoxin, selectively depletes acetylcholine in hippocampus and cortex, and produces long-term passive avoidance and radial-arm maze deficits in the rat
Brain Research 321: 91

Mantione CR, De Groat WC, Fisher A, Hanin I (1983)
Selective inhibition of peripheral cholinergic transmission in the cat produced by AF64A
Journal of Pharmacology & Experimental Therapeutics 225: 616

Mantione CR, Zigmond MJ, Fisher A, Hanin I (1983)
Selective presynaptic cholinergic neurotoxicity following intrahippocampal AF64A injection in rats
Journal of Neurochemistry 41: 251

Fisher A, Mantione CR, Abraham DJ, Hanin I (1982)
Long-term central cholinergic hypofunction induced in mice by ethylcholine aziridinium ion (AF64A) in vivo
Journal of Pharmacology & Experimental Therapeutics 222: 140

Fisher A, Hanin I (1980)
Choline analogs as potential tools in developing selective animal models of central cholinergic hypofunction
Life Sciences 27: 1615

Fisher A, Abraham S, Lachman C, Lass Y, Akselrod S, Akerman E, Cohen S (1980)
Does rigidity in structure of muscarinic agonists and antagonists reflect drug specificity?
Monogr Neural Sci 7: 41

Lass Y, Akselrod S, Gavish B, Cohen S, Fisher A (1979)
Offset rate of action of muscarinic antagonists depends on their structural flexibility
Experientia 35: 650

Fisher A, Grunfeld Y, Weinstock M, Gitter S, Cohen S (1976)
A study of muscarinic receptor heterogeneity with weak antagonists
European Journal of Pharmacology 38: 131